Literature DB >> 22263709

Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.

Peter D Friedmann1, Randall Hoskinson, Michael Gordon, Robert Schwartz, Timothy Kinlock, Kevin Knight, Patrick M Flynn, Wayne N Welsh, Lynda A R Stein, Stanley Sacks, Daniel J O'Connell, Hannah K Knudsen, Michael S Shafer, Elizabeth Hall, Linda K Frisman.   

Abstract

Medication-assisted treatment (MAT) is underutilized in the treatment of drug-dependent, criminal justice populations. This study surveyed criminal justice agencies affiliated with the Criminal Justice Drug Abuse Treatment Studies (CJ-DATS) to assess use of MAT and factors influencing use of MAT. A convenience sample (N = 50) of criminal justice agency respondents (e.g., jails, prisons, parole/probation, and drug courts) completed a survey on MAT practices and attitudes. Pregnant women and individuals experiencing withdrawal were most likely to receive MAT for opiate dependence in jail or prison, whereas those reentering the community from jail or prison were the least likely to receive MAT. Factors influencing use of MAT included criminal justice preferences for drug-free treatment, limited knowledge of the benefits of MAT, security concerns, regulations prohibiting use of MAT for certain agencies, and lack of qualified medical staff. Differences across agency type in the factors influencing use and perceptions of MAT were also examined. MAT use is largely limited to detoxification and maintenance of pregnant women in criminal justice settings. Use of MAT during the community reentry period is minimal. Addressing inadequate knowledge and negative attitudes about MAT may increase its adoption, but better linkages to community pharmacotherapy during the reentry period might overcome other issues, including security, liability, staffing, and regulatory concerns. The CJ-DATS collaborative MAT implementation study to address inadequate knowledge, attitudes, and linkage will be described.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22263709      PMCID: PMC3295578          DOI: 10.1080/08897077.2011.611460

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  18 in total

1.  Is the world finally waking up to HIV/AIDS in prisons? A report from the XV International AIDS Conference.

Authors: 
Journal:  HIV AIDS Policy Law Rev       Date:  2004-12

2.  Attitudes and practices regarding the use of methadone in US state and federal prisons.

Authors:  Josiah D Rich; Amy E Boutwell; David C Shield; R Garrett Key; Michelle McKenzie; Jennifer G Clarke; Peter D Friedmann
Journal:  J Urban Health       Date:  2005-05-25       Impact factor: 3.671

3.  SCREENING, ASSESSMENT, AND REFERRAL PRACTICES IN ADULT CORRECTIONAL SETTINGS : A National Perspective.

Authors:  Faye S Taxman; Karen L Cropsey; Douglas W Young; Harry Wexler
Journal:  Crim Justice Behav       Date:  2007-09

Review 4.  An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research.

Authors:  Laura Amato; Marina Davoli; Carlo A Perucci; Marica Ferri; Fabrizio Faggiano; Richard P Mattick
Journal:  J Subst Abuse Treat       Date:  2005-06

5.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

Review 6.  Methadone maintenance treatment (MMT): a review of historical and clinical issues.

Authors:  H Joseph; S Stancliff; J Langrod
Journal:  Mt Sinai J Med       Date:  2000 Oct-Nov

Review 7.  Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials.

Authors:  Henry R Kranzler; Allyson Gage
Journal:  Am J Addict       Date:  2008 Jan-Feb

Review 8.  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.

Authors: 
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

Review 9.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

10.  Naltrexone in the treatment of alcohol dependence.

Authors:  J R Volpicelli; A I Alterman; M Hayashida; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1992-11
View more
  72 in total

1.  Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Sharon M Kelly; Kevin E O'Grady; Jerome H Jaffe; Yngvild K Olsen; Robert P Schwartz
Journal:  J Drug Issues       Date:  2014-01

2.  Receipt of Pharmacotherapy for Alcohol Use Disorder by Male Justice-Involved U.S. Veterans Health Administration Patients.

Authors:  Andrea K Finlay; Ingrid Binswanger; Christine Timko; Joel Rosenthal; Sean Clark; Jessica Blue-Howells; Jim McGuire; Hildi Hagedorn; Jessie Wong; James Van Campen; Alex H S Harris
Journal:  Crim Justice Policy Rev       Date:  2016-04-18

3.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

4.  Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia.

Authors:  Hilary L Surratt; Michele Staton; Carl G Leukefeld; Carrie B Oser; J Matthew Webster
Journal:  J Addict Dis       Date:  2018-12-21

5.  A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.

Authors:  Michael S Gordon; Frank J Vocci; Faye Taxman; Marc Fishman; Bikash Sharma; Thomas R Blue; Kevin E O'Grady
Journal:  Contemp Clin Trials       Date:  2019-02-20       Impact factor: 2.226

6.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

Authors:  Lydia Aletraris; Mary Bond Edmond; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2015-01       Impact factor: 2.582

7.  Medication-Assisted Treatment and Violent Outcomes in Community-Based Offenders with Alcohol and Drug Use Problems.

Authors:  Sarah L Desmarais; Julie S Gray; Candalyn B Rade; Amy M Cohn; Stephen Doherty; Kevin Knight
Journal:  Psychol Violence       Date:  2016-03-24

8.  Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Authors:  Andrea K Finlay; Ingrid A Binswanger; Christine Timko; David Smelson; Matthew A Stimmel; Mengfei Yu; Tom Bowe; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2018-10-02

9.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

10.  The impact of the opioid crisis on U.S. state prison systems.

Authors:  Christy K Scott; Michael L Dennis; Christine E Grella; Allison F Mischel; John Carnevale
Journal:  Health Justice       Date:  2021-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.